Johnson & Johnson (JNJ) Minority Interest (2010 - 2023)
Johnson & Johnson (JNJ) posted Minority Interest of $1.3 billion for Q3 2023, up 113.56% sequentially from $590.0 million in Q1 2010.
Johnson & Johnson (JNJ) Minority Interest (2010 - 2023) Analysis & Trends
Johnson & Johnson (JNJ) has 2 years of Minority Interest data on file, last reported at $1.3 billion in Q3 2023.
- Quarterly Minority Interest changed N/A year-over-year to $1.3 billion in Q3 2023, while the trailing twelve-month figure through Jul 2023 was $1.3 billion (changed N/A YoY) and the FY2010 annual result came in at $590.0 million, changed N/A from the prior year.
- Minority Interest rose to $1.3 billion in Q3 2023 per JNJ's latest filing, from $590.0 million in the prior quarter.
- The five-year high for Minority Interest was $1.3 billion in Q3 2023, with the low at $1.3 billion in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 2, 2023 | 1.26 Bn |
| Jan 3, 2010 | 590.00 Mn |